Annual revenue moved from KRW 3.65 billion in 2022 to KRW 897 million in 2023 (down 75.4% year on year), KRW 1.21 billion in 2024 (up 34.6%), and KRW 381 million in 2025 (down 68.4%). 2022 was the largest year in the period and 2025 the smallest.
The operating loss was KRW 6.6 billion in 2022, KRW 9.48 billion in 2023, KRW 10.1 billion in 2024 and KRW 9.69 billion in 2025, a run of four consecutive loss-making years from 2022 through 2025. Revenue rose in 2024, yet the operating loss widened, so the recovery in sales did not translate into better profit.
The operating margin was -180.8% in 2022, -1,057.3% in 2023, -837.6% in 2024 and -2,541.0% in 2025. Because the revenue base shrank, the ratio deteriorated sharply, meaning fixed costs far exceeded sales.
The company attributed the 2025 revenue decline to weaker demand for molecular diagnostics after the COVID-19 endemic phase, a failed supply agreement in India and delayed next-generation equipment launches.
Net loss attributable to controlling shareholders was KRW 9 billion in 2022, KRW 7.92 billion in 2023, KRW 8.92 billion in 2024 and KRW 12 billion in 2025. Net loss including non-controlling interests was KRW 14.7 billion in 2025, larger than the controlling-shareholder figure.
Operating cash flow was negative every year from 2022 to 2025, at KRW -6.88 billion in 2025.
Quarterly revenue went from KRW 90.05 million in the third quarter of 2025 to KRW 158 million in the fourth quarter, KRW 329 million in the first quarter of 2026, KRW 432 million in the second quarter, and KRW 7.69 billion in the third quarter, up 1,678.9% from the prior quarter.
The operating loss narrowed from KRW 3.01 billion in the fourth quarter of 2025 to KRW 1.61 billion, KRW 958 million and KRW 761 million in the first three quarters of 2026.
Because the third-quarter revenue jump falls in the same quarter as the subsidiary's acquisition on July 30, 2026, consolidation effects and existing-business effects need to be separated by segment.
Net income attributable to controlling shareholders of KRW 4.18 billion in the third quarter is a turn to profit that exceeds the operating loss, so the non-operating income composition is a point to examine in the 2026 annual report.
Over the last four quarters, the cumulative net loss attributable to controlling shareholders was KRW 4.07 billion.